INSPIRE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Inspire Medical Systems, Inc. on Behalf of Inspire Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Inspire Medical Systems, Inc. for possible violations of federal securities laws and unlawful business practices following a significant reduction in the company's earnings guidance for fiscal 2025 [1][3]. Financial Performance - On August 5, 2025, Inspire reported better-than-expected second quarter results but drastically cut its full-year earnings guidance from $2.20 - $2.30 to $0.40 - $0.50, and revenue expectations from $940 million - $955 million to $900 million - $910 million [3]. - The company attributed the guidance reduction to challenges in the rollout of Inspire V, including training and onboarding issues, customer delays, and technical Medicare adoption delays [3]. Stock Market Reaction - Following the announcement of the revised guidance, Inspire's stock price dropped by $46.44, opening at $83.51 per share [4].